{"commentary":{"count":32,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":22,"podcast":6,"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05207670\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MorningSun","nct_id":"NCT05207670","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=morningsun-nct05207670. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MorningSun","arms":[{"description":"Participants with high tumor burden with untreated follicular lymphoma (FL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. Participants that achieve complete or partial metabolic response will have the option of receiving maintenance therapy with mosunetuzumab every 8 weeks for 1 year.","label":"Cohort A","type":"EXPERIMENTAL"},{"description":"Elderly participants with untreated diffuse large B-cell lymphoma (DLBCL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.","label":"Cohort B","type":"EXPERIMENTAL"},{"description":"Participants with untreated marginal zone lymphoma (MZL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.","label":"Cohort C","type":"EXPERIMENTAL"},{"description":"Participants with relapsed or refractory (R/R) mantle cell lymphoma (MCL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.","label":"Cohort D","type":"EXPERIMENTAL"},{"description":"Participants with R/R Richter's transformation (RT), or R/R transformed follicular lymphoma (tFL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.","label":"Cohort E","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"conditions":["Non-Hodgkin Lymphoma"],"enrollment":{"count":320,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Mosunetuzumab (Cohorts A-C)","type":"DRUG"},{"name":"Mosunetuzumab (Cohorts D-E)","type":"DRUG"},{"name":"Tocilizumab","type":"DRUG"}],"last_update":"2026-08-31","lead_sponsor":"Genentech, Inc.","official_title":"An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) rate at 24 months after the first study treatment (Cohorts A1, A2, and B)","timeFrame":"From the first study treatment to the first occurrence of disease progression, relapse, or death from any cause, whichever occurs first, as determined by the investigator according to Lugano Criteria 2014 (minimum 2 years)"},{"measure":"Objective response rate (ORR), defined as the proportion of participants with a complete metabolic response (CMR) or partial response (PR), as determined by the investigator according to the Lugano Criteria 2014 (Cohorts C, D, and E)","timeFrame":"Cycles 4, 8, 12 and 17 (cycle length=21 days)"}],"references":[],"start_date":{"date":"2022-02-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","url":"https://clinicaltrials.gov/study/NCT05207670"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/morningsun-nct05207670"}